Key TakeawaysBoston Scientific's second-quarter earnings and revenue got a boost from high demand for its heart devices.Sales of cardiovascular products made up more than half of the company's revenue in the period.Boston Scientific raised its full-year adjusted earnings per share (EPS) and revenue growth estimates. Boston Scientific (BSX) posted an increase in second-quarter earnings and sales on the back of growing demand for its heart devices. The medical device maker recorded adjusted earnings per share ...

Boston Scientific Corporation (NYSE:BSX) Q2 2024 Earnings Conference Call July 24, 2024 8:00 AM ET Company Participants Jon Monson - SVP, IR Michael F. Mahoney - Chairman and CEO Daniel J. Brennan - EVP and CFO Kenneth Stein - SVP, Global Chief Medical Officer Conference Call Participants Robert Marcus - J.P. Morgan Joanne Wuensch - Citigroup Inc. Lawrence Biegelsen - Wells Fargo Securities Frederick Wise - Stifel, Nicolaus & Company Vijay Kumar - Evercore ISI David Roman - Goldman Sachs Patrick Wood - Morg ...

Boston Scientific (BSX) reported $4.12 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 14.5%. EPS of $0.62 for the same period compares to $0.53 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $4.02 billion, representing a surprise of +2.51%. The company delivered an EPS surprise of +6.90%, with the consensus EPS estimate being $0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Boston Scientific (BSX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.90%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.51 per share when it actually produced earnings of $0.56, delivering a surprise of 9.80%.Over the last four qua ...

Q2 2024 Highlights July 24, 2024 1 Q2 2024 Financial & Operational Highlights | July 24, 2024 Safe Harbor for Forward-Looking Statements and Use of Document Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forwardlooking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "inten ...

Boston Scientific Announces Results for Second Quarter 2024 Marlborough, Mass. (July 24, 2024) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational basis and 14.7 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared t ...

MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, ...

UKRAINE - 2021/06/17: In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific (NYSE: BSX) is scheduled to report its Q2 2024 results on Wednesday, July 24. We expect the company to report revenues and earnings in line with the consensus estimates. A rise in elective surgeries performed and mar ...

Boston Scientific (BSX) is gaining traction in the emerging markets. New regulatory approvals bode well for the company’s growth. The stock carries a Zacks Rank #2 (Buy) currently.Boston Scientific is consistently gaining market share within its MedSurg segment. The Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options. In the first quarter of 2024, the company reported strong organic growth contribution from single- ...

Goodboy Picture Company/E+ via Getty ImagesBoston Scientific (NYSE:BSX) is set to report its second-quarter earnings on July 24. Expectations are high for this medical technologies giant following what has been an impressive share price rally in the first half of 2024. The stock is up 35% year-to-date, well ahead of healthcare sector benchmarks. We last covered BSX ahead of its first quarter report back in April highlighting the company's financial momentum, with new product launches driving a growth re ...